Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Rheumatology (Oxford) ; 49(4): 662-70, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20097906

ABSTRACT

OBJECTIVE: B cells lacking RP105 produce autoantibodies in patients with SLE. Expression of B-cell activating factor (BAFF) binding receptors (BBRs) and survival of RP105(-) B cells from SLE patients were examined. METHODS: Detection of difference of gene expression between RP105(-) and RP105(+) B cells was done by DNA microarrays. Surface expression was confirmed by flow cytometry. The contribution of BAFF, a proliferation-inducing ligand (APRIL) and monomers/trimers of sCD40L to survival of RP105(-) and RP105(+) B cells was examined. RESULTS: Gene expression of B-cell maturation antigen (BCMA) was different among BBRs in RP105(-) and RP105(+) B cells in SLE. Preferential expression of BCMA on RP105(-) B cells was confirmed compared with RP105(+) B cells by flow cytometry, although BAFF receptor (BAFF-R) expression on RP105(-) B cells was significantly lower. Additionally, relative ratios of BCMA/BAFF-R expression on RP105(-) B cells were increased significantly in SLE patients compared with normal subjects. Stimulation by sCD40L decreased the number of surviving RP105(-) and RP105(+) B cells in vitro. RP105(+) B cells were not rescued from sCD40L-induced cell death by BAFF and/or APRIL. In contrast, either BAFF or APRIL maintained the survival of RP105(-) B cells due to avoidance of cell death. Activated RP105(-) B cells reduced BAFF-R and increased BCMA levels. CONCLUSIONS: RP105(-) B cells from SLE patients showed more preferential expression of BCMA compared with BAFF-R than normal subjects, and were possibly regulated by BAFF/APRIL. Our results provide a new insight of BCMA and their ligands in B cells from SLE patients.


Subject(s)
Autoantibodies/immunology , B-Cell Activation Factor Receptor/immunology , B-Cell Maturation Antigen/immunology , Lupus Erythematosus, Systemic/immunology , Adolescent , Adult , Aged , B-Cell Activation Factor Receptor/genetics , B-Cell Maturation Antigen/genetics , Case-Control Studies , Female , Flow Cytometry , Humans , Lupus Erythematosus, Systemic/genetics , Male , Middle Aged , Polymerase Chain Reaction , Young Adult
2.
Mod Rheumatol ; 19(2): 173-9, 2009.
Article in English | MEDLINE | ID: mdl-19067109

ABSTRACT

To assess the effects of disease activity of systemic lupus erythematosus (SLE) and high-dose corticosteroids on endothelial injuries, the significance of soluble endothelial cell protein C receptor (sEPCR) and soluble thrombomodulin (sTM) was analyzed. Serum levels of sEPCR and sTM were measured by enzyme-linked immunosorbent assay (ELISA) cross-sectionally in 97 SLE patients, 49 patients with other rheumatic diseases and 22 normal subjects. The changes in these levels upon corticosteroid treatment were also analyzed in 41 patients. The levels of sEPCR and sTM were both higher in SLE and other rheumatic disease patients than in normal subjects. When low-dose corticosteroids were used, both the level of sEPCR and the ratio of positive tests for sEPCR were significantly higher in active SLE patients than in inactive patients [median 2.30 ng/ml (range 0.00-147.10 ng/ml) vs 0.00 ng/ml (0.00-58.90 ng/ml) and 53.5 vs 13.0%, respectively] (P < 0.005). Moreover, the ratio of positive tests for sEPCR was higher after corticosteroid treatment in 9 of 19 (47.3%) SLE patients compared to other rheumatic diseases (3/22; 13.6%). Although the mean level of sTM was significantly higher in active SLE patients than in inactive patients, the ratio of positive tests for sTM was not affected by disease activity or corticosteroids. In conclusion, the positive test for sEPCR is a more sensitive biomarker than that for sTM in reflecting endothelial injuries caused by active disease and often by corticosteroids in SLE.


Subject(s)
Adrenal Cortex Hormones/pharmacology , Antigens, CD/blood , Lupus Erythematosus, Systemic/blood , Receptors, Cell Surface/blood , Adrenal Cortex Hormones/therapeutic use , Adult , Disease Progression , Endothelial Protein C Receptor , Female , Humans , Lupus Erythematosus, Systemic/drug therapy , Male , Middle Aged , Thrombomodulin/blood
3.
Scand J Infect Dis ; 39(6-7): 577-83, 2007.
Article in English | MEDLINE | ID: mdl-17577821

ABSTRACT

Toll-like receptor 4 (TLR4) recognizes lipopolysaccharide (LPS) and other exogenous and endogenous molecules, and is thought to contribute to defense mechanisms against infections. Our objective was to elucidate the clinical significance of TLR4 in acute infectious diseases by analyzing its sequential expression on CD14+ monocytes. Peripheral blood samples were obtained from 36 patients with acute infectious diseases on admission and after treatment within certain intervals. The TLR4 expression on CD14+ monocytes was analyzed using flow cytometry and was presented as a mean fluorescence intensity (MFI). TLR4 expression during the acute phase of infection was highly enhanced compared to that of normal subjects (MFI: 22.1 vs 8.5). TLR4 expression was promptly reduced to normal levels in parallel with the disease improvement. In patients who died despite treatment, the enhancement of TLR4 expression during the acute phase was less prominent compared to those who survived (MFI: 14.6 vs 23.5) and its sequential change was also subtle. These results indicate that monocytes respond to acute infections by the induction of TLR4 expression and that a poor response may be associated with a poor prognosis.


Subject(s)
Communicable Diseases/immunology , Lipopolysaccharide Receptors/biosynthesis , Monocytes/immunology , Toll-Like Receptor 4/biosynthesis , Acute Disease , Adult , Aged , Aged, 80 and over , Communicable Diseases/microbiology , Communicable Diseases/mortality , Female , Humans , Lipopolysaccharide Receptors/immunology , Lipopolysaccharides/immunology , Male , Middle Aged , Monocytes/metabolism , Prognosis , Toll-Like Receptor 4/immunology
4.
Kansenshogaku Zasshi ; 81(3): 305-8, 2007 May.
Article in Japanese | MEDLINE | ID: mdl-17564121

ABSTRACT

A 21-year-old woman admitted for a low-grade fever, dry cough, polyarthralgia, and general fatigue was found to have elevateal accustomed to eating raw meat and cattle liver peripheral blood eosinophil counts and serum IgE. Chest X-ray imaging and computed tomography (CT) showed multiple small nodules in both lung fields. A multiple dot-ELISA assay of her serum showed that she had visceral larva migrans caused by Ascaris suum or Toxocara canis. Following treatment with albendazole, she developed myelopathy and was again admitted. A cerebrospinal fluid examination showed increased eosionophils and significant antibody elevation against T. canis. Her disease was considered to have entered the central nervous system, one of the target organs of visceral larva migrans. She was successfully treated with dietylcarbamazine and has shown no reccurrence. This case showed the different manifestations of visceral larva migrans and the rising incidence of this disease in Japan raises concerns about associated of diet.


Subject(s)
Larva Migrans, Visceral/complications , Toxocara canis , Adult , Animals , Female , Humans
5.
Mod Rheumatol ; 16(6): 364-71, 2006.
Article in English | MEDLINE | ID: mdl-17164998

ABSTRACT

We investigated the effect of hepatocyte growth factor (HGF) on collagen metabolism in cultured fibroblasts from scleroderma (SSc) patients and discussed the possible mechanism of its effect. Synthesis of matrix metalloproteinase-1 (MMP-1) and collagen and mRNA levels of various cytokines were examined by enzyme-linked immunosorbent assay and real-time polymerase chain reaction, respectively. Hepatocyte growth factor enhanced MMP-1 production and mRNA levels of MMP-1 and Ets-1 (a transcriptional factor of MMPs). In addition, HGF suppressed collagen synthesis and mRNA levels of procollagenalpha1(I) and connective tissue growth factor (CTGF) in SSc fibroblasts. Expression of transforming growth factor (TGF)-beta1 was not inhibited significantly in SSc or control fibroblasts. Hepatocyte growth factor also increased interferon (IFN)-gamma mRNA significantly in SSc and control fibroblasts. Addition of anti-HGF antibody neutralized these effects of HGF on MMP-1 and collagen synthesis. The results suggest that HGF can suppress collagen accumulation in SSc fibroblasts by increasing MMP-1 levels possibly via activation of Ets-1 and also by decreasing collagen synthesis, which may be partly related to inhibition of CTGF, and increasing IFN-gamma levels rather than the effect on TGF-beta1. The present study indicates that HGF may be a promising therapeutic agent for this intractable disease.


Subject(s)
Fibroblasts/pathology , Hepatocyte Growth Factor/pharmacology , Scleroderma, Diffuse/pathology , Scleroderma, Limited/pathology , Skin/pathology , Antibodies, Blocking/pharmacology , Cells, Cultured , Collagen/metabolism , Collagen Type I/genetics , Collagen Type I/metabolism , Collagen Type I, alpha 1 Chain , Connective Tissue Growth Factor , Cytokines/genetics , Cytokines/metabolism , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Female , Fibroblasts/drug effects , Hepatocyte Growth Factor/immunology , Humans , Immediate-Early Proteins/genetics , Immediate-Early Proteins/metabolism , Intercellular Signaling Peptides and Proteins/genetics , Intercellular Signaling Peptides and Proteins/metabolism , Male , Matrix Metalloproteinase 1/metabolism , Proto-Oncogene Protein c-ets-1/genetics , Proto-Oncogene Protein c-ets-1/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction
6.
Clin Immunol ; 120(2): 179-88, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16616645

ABSTRACT

Inducible costimulator (ICOS) is a costimulatory molecule expressed in activated T cells and plays an important role in T-cell-dependent immune responses. We investigated the role of ICOS in the development of autoimmune diseases in MRL/Mpj-lpr/lpr (MRL/lpr) mice. ICOS was expressed on CD4(+) T cells from adult MRL/lpr mice. ICOS-deficient MRL/lpr mice showed mild lymphoadenopathy and a decreased memory type CD4(+) T cells in the spleen. The anti-dsDNA antibody levels were decreased. CD4(+) T cells from ICOS-deficient MRL/lpr mice showed less of a bias to Th1 and an enhanced production of IL-4 in response to anti-CD3 antibody in comparison to those from wild-type MRL/lpr mice. Although ICOS-deficiency abrogated renal vasculitis completely, the severity of glomerulonephritis was not altered. ICOS is considered to play a role in CD4(+) T cell activation, autoantibody production, and renal vasculitis. However, it is not essentially required in the development of glomerulonephritis.


Subject(s)
Antigens, Differentiation, T-Lymphocyte/genetics , Antigens, Differentiation, T-Lymphocyte/physiology , Lupus Vulgaris/etiology , Animals , Cytokines/biosynthesis , Cytokines/blood , Disease Models, Animal , Female , Glomerulonephritis/complications , Glomerulonephritis/mortality , Immunoglobulins/blood , Inducible T-Cell Co-Stimulator Protein , Kidney/pathology , Lupus Vulgaris/complications , Lupus Vulgaris/immunology , Lymphatic Diseases/immunology , Mice , Mice, Inbred MRL lpr , Mice, Knockout , Spleen/cytology , Spleen/immunology , Splenomegaly/immunology , T-Lymphocytes/immunology
7.
J Rheumatol ; 32(3): 562-4, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15742454

ABSTRACT

B cells lacking RP105 molecule, a member of the Toll-like receptor family, were increased in the peripheral blood of 2 patients with antinuclear antibody (ANA) negative systemic lupus erythematosus (SLE). The increased proportion of RP105-lacking B cells was associated with disease activity in patients with ANA-negative SLE. When there are no significant serological markers for SLE, analysis of expression of RP105 may be helpful in evaluation of activity in ANA-negative SLE. We describe a new approach, using phenotyping of B cells, to evaluate activity of ANA-negative SLE.


Subject(s)
Antibodies, Antinuclear/immunology , Antigens, CD/immunology , B-Lymphocytes/metabolism , Lupus Erythematosus, Systemic/immunology , Adult , Antibodies, Antinuclear/blood , Antigens, CD/blood , Biomarkers , Brain/immunology , Brain/pathology , Humans , Lupus Erythematosus, Systemic/blood , Male
8.
Arthritis Rheum ; 48(11): 3280-90, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14613294

ABSTRACT

OBJECTIVE: Platelet endothelial cell adhesion molecule 1 (PECAM-1; CD31) is a member of the immunoglobulin superfamily that is expressed in platelets, leukocytes, and endothelial cells. PECAM-1 has been shown to play a role in transendothelial migration of leukocytes and contains immunoreceptor tyrosine-based inhibitory motifs in its cytoplasmic tail and inhibits cellular responses. We examined the role of PECAM-1 in the development of collagen-induced arthritis (CIA). METHODS: CIA was induced in PECAM-1-deficient DBA/1 mice. The incidence of arthritis and the arthritis index were examined. Anti-type II collagen (anti-CII) antibody levels and interferon-gamma (IFNgamma) production by lymph node cells and spleen cells were determined. Lymphocytes from arthritic PECAM-1-deficient and wild-type mice were labeled with dye, transferred to arthritic PECAM-1(+/-) mice, and cell migration to inflamed joints was examined. RESULTS: PECAM-1-deficient mice showed accelerated onset of arthritis and increased severity only during the early phase. Anti-CII antibody levels were also increased during the early phase. IFNgamma production by lymph node cells and spleen cells from PECAM-1-deficient mice in response to CII was higher than that in wild-type mice. Lymphocytes from arthritic PECAM-1-deficient mice showed accelerated migration to inflamed joints, but not lymph nodes or spleen. The development of anti-CII antibody-induced arthritis was similar in PECAM-1-deficient and wild-type mice. CONCLUSION: These results indicate that PECAM-1 negatively regulates humoral and cell-mediated immune responses and lymphocyte migration into joints and, consequently, the development of CIA. In addition, the role of PECAM-1 in the transendothelial migration of leukocytes appears to be redundant in this model.


Subject(s)
Arthritis, Experimental/metabolism , Collagen Type II , Platelet Endothelial Cell Adhesion Molecule-1/biosynthesis , Adoptive Transfer , Animals , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , Autoantibodies/blood , Cell Movement , Collagen Type II/immunology , Collagen Type II/pharmacology , Disease Models, Animal , Hindlimb/pathology , Immunoglobulin G/blood , Interferon-gamma/metabolism , Joints/pathology , Lymph Nodes/metabolism , Lymphocyte Activation/immunology , Mice , Mice, Inbred DBA , Mice, Knockout , Platelet Endothelial Cell Adhesion Molecule-1/genetics , Spleen/cytology , Spleen/metabolism , T-Lymphocytes/immunology
9.
Gan To Kagaku Ryoho ; 30(3): 371-5, 2003 Mar.
Article in Japanese | MEDLINE | ID: mdl-12669396

ABSTRACT

A multicenter cooperative study of docetaxel (60 mg/m2) combined with cisplatin (60 mg/m2) was performed in stage III and IV patients with inoperable non-small cell lung cancer from March 1998 to September 1999. Of 37 patients enrolled, 36 patients were eligible. One patient obtained a complete response (CR) and nine patients had a partial response (PR). The overall response rate in 36 patients was 28.6%. The median survival time was 360 days. The response rates of stage III and stage IV patients were 36.8% and 18.7%, respectively. The median survival times of stage III and stage IV patients were 502 days and 286 days, respectively. The major toxicities were grade 3 leukopenia (16.2%), grade 3 neutropenia (32.4%), and grade 4 neutropenia (10.8%).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Paclitaxel/analogs & derivatives , Taxoids , Adult , Aged , Carcinoma, Non-Small-Cell Lung/mortality , Cisplatin/administration & dosage , Docetaxel , Drug Administration Schedule , Female , Humans , Lung Neoplasms/mortality , Male , Middle Aged , Paclitaxel/administration & dosage , Survival Rate
10.
Ryumachi ; 42(6): 872-8, 2002 Dec.
Article in Japanese | MEDLINE | ID: mdl-12632606

ABSTRACT

We investigated the features and the usefulness of gallium scintigraphy in the diagnosis and the assessment of Adult Still's disease (ASD) by retrospective case review. Gallium scintigraphy have been done for 11 cases of ASD (3 males and 8 females) and 4 females were positive. Among these, 67 Ga-citrate was accumulated to the bone marrow in all 4 cases and to the major joints in 2 cases. Positive cases were rather serious and administered more immunosuppressants than negative cases. In order to characterize gallium scintigraphy findings of ASD, i.e. bone marrow accumulation, we analyzed 130 cases of collagen vascular diseases. Although 101 cases (77.7%) were positive, only 7 cases (5.4%) showed the accumulation of 67Ga-citrate to the bone marrow. These include 3 cases with ASD, and 1 case with systemic lupus erythematosus, polyarteritis nodosa, Wegener's granulomatosis and Sjögren's syndrome. We also accumulated 18 patients who exhibited bone marrow accumulation of 67Ga-citrate, and found that 7 patients had collagen vascular and their related diseases. In conclusion, bone marrow accumulation in gallium scintigraphy is a specific feature of collagen vascular diseases, especially ASD, and it is suggested that cases with positive gallium scintigraphy in ASD can be serious and resistant to treatment.


Subject(s)
Bone Marrow/diagnostic imaging , Bone Marrow/metabolism , Citrates , Gallium Radioisotopes , Gallium , Radiopharmaceuticals , Adult , Aged , Citrates/pharmacokinetics , Diagnosis, Differential , Female , Gallium/pharmacokinetics , Gallium Radioisotopes/pharmacokinetics , Humans , Male , Middle Aged , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Retrospective Studies , Still's Disease, Adult-Onset
SELECTION OF CITATIONS
SEARCH DETAIL
...